Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.

Saved in:
Bibliographic Details
Title: Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.
Authors: Young G; Hemostasis and Thrombosis Center, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA., Kavakli K; Department of Pediatric Hematology and Oncology, Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey., Klamroth R; Department for Internal Medicine and Vascular Medicine, Haemophilia Treatment Centre, Vivantes Hospital im Friedrichshain, Berlin, Germany., Matsushita T; Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan., Peyvandi F; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy., Pipe SW; Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI., Rangarajan S; Advanced Centre for Oncology, Haematology and Rare Diseases, K.J. Somaiya Super Specialty Hospital, Mumbai, India.; Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Shen MC; Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.; Department of Laboratory Medicine and Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Srivastava A; Haematology Research Unit, St. Johns Research Institute and Department of Clinical Haematology, St. John's Medical College Hospital, Bengaluru, India., Sun J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China., Tran H; Ronald Sawers Hemophilia Treatment Center, The Alfred Hospital, Monash University, Melbourne, VIC, Australia., You CW; Department of Pediatrics, Eulji University School of Medicine, Seoul, Republic of Korea., Zülfikar B; Division of Pediatric Hematology-Oncology, Istanbul University Oncology Institute, Istanbul, Turkey., Menapace LA; Sanofi, Cambridge, MA., Zhang C; Sanofi, Waltham, MA., Shen Y; Sanofi, Bridgewater, NJ., Puurunen M; Sanofi, Cambridge, MA., Demissie M; Sanofi, Cambridge, MA., Kenet G; National Hemophilia Centre, Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Ramat Gan, Israel.
Source: Blood [Blood] 2025 Jun 19; Vol. 145 (25), pp. 2966-2977.
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2024027008